<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068767</url>
  </required_header>
  <id_info>
    <org_study_id>TZ-105</org_study_id>
    <nct_id>NCT03068767</nct_id>
  </id_info>
  <brief_title>The Relationship Between Vitamin D and Hepatitis B Virus Replication</brief_title>
  <official_title>Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</source>
  <brief_summary>
    <textblock>
      149 HBV carriers with inadequate serum vitamin D levels were randomized to two groups: one is
      supplied with vitamin D and another without as controls. The markers of HBV replication were
      compared before and after treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized case-control trial. A total of 149 HBV carriers with inadequate vitamin
      D (&lt; 30 ng/mL) level were enrolled. They were randomly divided to two groups: one group
      receiving vitamin D supplement (1600 IU/day) for 2 months and another group as controls. The
      serum vitamin D, HBV DNA and qHBsAg levels were measured at baseline and after vitamin D
      supplement. Whether HBV DNA and qHBsAg have significant change after vitamin D supplement can
      be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">January 15, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1: vitamin D supplement Group 2: controls</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Dynamic Change of HBV DNA</measure>
    <time_frame>baseline, after 2-month vitamin D supplement</time_frame>
    <description>the serum HBV DNA levels were measured in CH-B patients before and after 2-month vitamin D supplement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change of Serum qHBsAg (IU/mL)</measure>
    <time_frame>baseline, after 2-month vitamin D supplement</time_frame>
    <description>The serum qHBsAg levels were measured before and after 2-month vitamin D supplement</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Vitamin D and Hepatitis B Virus</condition>
  <arm_group>
    <arm_group_label>Vitamin D group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving vitamin D supplement (2000 IU/day) for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients without receiving vitamin D supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>Vitamin D group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;20 y/o, HBV carrier

          -  serum vitamin D &lt; 30ng/ml

        Exclusion Criteria:

          -  Other known causes of hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia-Chi CC Wang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</name>
      <address>
        <city>New Taipei city</city>
        <zip>23142</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <results_first_submitted>April 13, 2019</results_first_submitted>
  <results_first_submitted_qc>February 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2020</results_first_posted>
  <last_update_submitted>February 1, 2020</last_update_submitted>
  <last_update_submitted_qc>February 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</investigator_affiliation>
    <investigator_full_name>Chia-Chi Wang</investigator_full_name>
    <investigator_title>Department of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>HBV DNA, qHBsAg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03068767/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03068767/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Chronic HBV patients receiving regular 6-month surveillance in the outpatient clinic of Taipei Tzu Chi Hospital were invited to join the study from August 2017 to September 2018.</recruitment_details>
      <pre_assignment_details>All had positive hepatitis B surface antigen (HBsAg) for more than 6 months. Those with positive anti-hepatitis C virus (HCV) antibody, other known causes of chronic hepatitis or receiving antiviral treatment currently were excluded. Those who had HBsAg loss, undetectable HBV DNA and adequate vitamin D level (â‰¥30 ng/mL) were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D Group</title>
          <description>Patients receiving vitamin D supplement (2000 IU/day) for 2 months
Vitamin D</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Patients without receiving vitamin D supplement</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75">from August 2017 to September 2018</participants>
                <participants group_id="P2" count="74">from August 2017 to September 2018</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65">December 2018</participants>
                <participants group_id="P2" count="71">December 2018</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Those who had HBsAg loss, undetectable HBV DNA and adequate vitamin D level (â‰¥30 ng/mL) were excluded. The eligible subjects were randomized into two groups by using the computer random distribution.</population>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D Group</title>
          <description>Patients receiving vitamin D supplement (2000 IU/day) for 2 months
Vitamin D</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Patients without receiving vitamin D supplement</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="75"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Those who had HBsAg loss, undetectable HBV DNA and adequate vitamin D level (â‰¥30 ng/mL) were excluded. The eligible subjects were randomized into two groups by using the computer random distribution.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="75"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.85" spread="10.88"/>
                    <measurement group_id="B2" value="51.28" spread="8.86"/>
                    <measurement group_id="B3" value="51.61" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Those who had HBsAg loss, undetectable HBV DNA and adequate vitamin D level (â‰¥30 ng/mL) were excluded. The eligible subjects were randomized into two groups by using the computer random distribution.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="75"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Dynamic Change of HBV DNA</title>
        <description>the serum HBV DNA levels were measured in CH-B patients before and after 2-month vitamin D supplement</description>
        <time_frame>baseline, after 2-month vitamin D supplement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Group</title>
            <description>Patients receiving vitamin D supplement (2000 IU/day) for 2 months
Vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients without receiving vitamin D supplement</description>
          </group>
        </group_list>
        <measure>
          <title>The Dynamic Change of HBV DNA</title>
          <description>the serum HBV DNA levels were measured in CH-B patients before and after 2-month vitamin D supplement</description>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="1.14"/>
                    <measurement group_id="O2" value="3.14" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change of Serum qHBsAg (IU/mL)</title>
        <description>The serum qHBsAg levels were measured before and after 2-month vitamin D supplement</description>
        <time_frame>baseline, after 2-month vitamin D supplement</time_frame>
        <population>Levels of qHBsAg before and after 2 months of vitamin D treatment or follow-up were compared between these two groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Group</title>
            <description>Patients receiving vitamin D supplement (2000 IU/day) for 2 months
Vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients without receiving vitamin D supplement</description>
          </group>
        </group_list>
        <measure>
          <title>The Change of Serum qHBsAg (IU/mL)</title>
          <description>The serum qHBsAg levels were measured before and after 2-month vitamin D supplement</description>
          <population>Levels of qHBsAg before and after 2 months of vitamin D treatment or follow-up were compared between these two groups.</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="1.03"/>
                    <measurement group_id="O2" value="2.4" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <desc>Death: 0% Serious adverse event: 0% adverse event: 6%</desc>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D Group</title>
          <description>Patients receiving vitamin D supplement (2000 IU/day) for 2 months
Vitamin D
No serious adverse events noted.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Patients without receiving vitamin D supplement
No serious adverse events noted.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>sneezing</sub_title>
                <description>sneezing</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>tearing</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>increased tear</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>acid reflux</sub_title>
                <description>sometimes acid reflux</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>leg soreness</sub_title>
                <description>leg soreness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urine occult blood positive</sub_title>
                <description>Positive urine occult blood in urinalysis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <description>feel difficulty in breathing</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <description>skin rash over legs</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief of internal medicine department</name_or_title>
      <organization>Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</organization>
      <phone>+886-2-6628-9779 ext 2317</phone>
      <email>uld888@yahoo.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

